Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.
ZURICH The activist investor fighting Clariant's planned $20 billion (14.78 billion pounds) merger with Huntsman Corp has built a 15.1 percent stake that makes it the biggest shareholder in the Swiss chemicals maker.
ZURICH Switzerland could become the latest country to ban facial coverings worn by some Muslim women after activists collected more than the 100,000 signatures required to put the proposal to a national vote.
ZURICH Specialty chemicals maker Clariant's proposed merger with U.S.-based Huntsman may catapult the combined company into Switzerland's blue-chip Swiss Market Index, lifting its appeal for funds focusing on the largest Swiss companies.
ZURICH Investigators in Zurich, ranked among the world's cleanest cities, are probing alleged grubby dealings within the municipal garbage and recycling department.
ZURICH Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs.
ZURICH/MADRID Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group.
ZURICH A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future.
ZURICH Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. | Video
ZURICH Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.